Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
LogicBio Therapeutics, Inc. (LOGC) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/16/2022 8-K Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Fa...
Docs: "Fifth Amended and Restated Certificate of Incorporation of LogicBio Therapeutics, Inc",
"Amended and Restated Bylaws of LogicBio Therapeutics, Inc"
10/20/2022 8-K Quarterly results
10/07/2022 8-K Entry into a Material Definitive Agreement  Interactive Data
10/03/2022 8-K Quarterly results
09/23/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Consulting Agreement by and between Cecilia Jones and LogicBio Therapeutics, Inc., effective as of September 23, 2022",
"Consulting Agreement by and between Cecilia Jones and LogicBio Therapeutics, Inc., effective as of September 23, 2022"
09/20/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
09/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/15/2022 8-K Quarterly results
06/21/2022 8-K Quarterly results
05/16/2022 8-K Quarterly results
03/18/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
03/04/2022 8-K Quarterly results
02/02/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program"
12/22/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "LogicBio Therapeutics Provides Business Updates"
11/15/2021 8-K Quarterly results
Docs: "LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones"
10/18/2021 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "LogicBio Therapeutics Announces Early Clinical Trial Results Demonstrating First-Ever In Vivo Genome Editing in Children"
08/09/2021 8-K Quarterly results
06/15/2021 8-K Quarterly results
06/02/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
12/22/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/14/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/09/2020 8-K Quarterly results
Docs: "LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update"
11/03/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer LEXINGTON, Mass., Nov. 3, 2020 - LogicBio Therapeutics, Inc. , a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the appointment of Mariana Nacht, Ph.D., as chief scientific officer, effective Nov. 30, 2020, and the promotion of Kyle Chiang, Ph.D., to chief operating officer, effective Nov. 2, 2020. Dr. Nacht brings more than 20 years of experience in both large and small biotech companies to her role at LogicBio. Most recently, she served as CSO and was a founding executive team member of Cereius, where she led a small internal research..."
10/05/2020 8-K Quarterly results
09/30/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
06/25/2020 8-K Quarterly results
06/17/2020 8-K Quarterly results
05/11/2020 8-K Quarterly results
Docs: "LogicBio Reports First Quarter 2020 Financial Results and Provides Business Updates LEXINGTON, Mass., May 11, 2020 - LogicBio Therapeutics, Inc. , a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today reported financial results for the quarter ended March 31, 2020 and provided a business update. “We remain committed to advancing LB-001 to the clinic for methylmalonic acidemia as quickly as possible. We have had preliminary interactions with the FDA regarding their questions on our IND for LB-001 and plan to continue these interactions through the middle of the year. We look forward to providing an update on the anticipated timing for the initiation of our Phase 1/2 clinical trial for LB-001 after we complete these interactions,..."
03/20/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy